Status:
COMPLETED
Effect of Methyldopa on MHC Class II Antigen Presentation in Type 1 Diabetes
Lead Sponsor:
University of Colorado, Denver
Collaborating Sponsors:
Juvenile Diabetes Research Foundation
Conditions:
Diabetes Mellitus, Type 1
Eligibility:
All Genders
18-46 years
Phase:
NA
Brief Summary
Type 1 Diabetes is an autoimmune condition in which segments of the immune system cause the destruction of insulin producing cells in the pancreas, leaving individuals with an impaired ability to cont...
Eligibility Criteria
Inclusion
- Diagnosis of Type 1 Diabetes Mellitus
- 18-46 years of age
- Residual C-peptide production during screening
- Positive for at least one islet autoantibody: insulin (if only insulin autoantibody positive, determination must be within two weeks of insulin initiation), GAD-65, IA-2 or ZnT8
- Positive for at least one gene encoding HLA-DQ8 (DQB\*0302)
- No history of difficult to control hypertension (defined as requiring \> 2 anti-hypertensive medications)
- Agree to intensive management of diabetes with an HgbA1c goal of \< 8.0%
- If female: (a) surgically sterile or (b) postmenopausal or (c) if of reproductive potential, willing to use medically acceptable birth control (e.g. female hormonal contraception, barrier methods or sterilization.) until study completion
- If male and of reproductive potential, willing to use medically acceptable birth control until study completion, unless the female partner is postmenopausal or surgically sterile
Exclusion
- Unable or unwilling to comply with the requirements of the study protocol
- No HLA-DQ8 gene (DQB\*0302)
- Difficult to control hypertension (defined as requiring \> 2 anti-hypertensive medications)
- History of postural hypotension or Addison's disease
- Body Mass Index (BMI) \> 30 kg/m2
- Unstable blood sugar control defined as one or more episodes of severe hypoglycemia (defined as hypoglycemia that required the assistance of another person) within the last 30 days
- Administration of an experimental agent for T1D at any time or use of an experimental device for T1D within 30 days of screening, unless approved by the study PI
- History of any organ transplant, including islet cell transplant
- Active autoimmune or immune deficiency disorder (e.g. sarcoidosis, rheumatoid arthritis)
- Anticipated pregnancy during the 12 week study period
- Any social or medical condition that would, in the opinion of the investigator, prevent complete participation in the study or that would pose a significant hazard to the subjects' participation
- History of active substance abuse within 12 months of screening
- A psychiatric or medical disorder that would prevent giving informed consent
Key Trial Info
Start Date :
June 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2016
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01883804
Start Date
June 1 2013
End Date
February 1 2016
Last Update
January 18 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Barbara Davis Center for Diabetes, University of Colorado School of Medicine
Aurora, Colorado, United States, 80045